Stockreport

What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF FDA accepted and granted Priority Review to its New Drug Application for brepocitinib in dermatomyositis, with a PDUFA action date set for the third quarter of 2026 and [Read more]